Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Takeda To Acquire URL Pharma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Takeda To Acquire URL Pharma

Gains leading gout drug Colcrys

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Takeda Pharmaceutical Co. has entered an agreement to acquire URL Pharma, a privately held pharmaceutical company based in Philadelphia, PA, for an upfront payment of $800 million and future performance-based milestones. Upon closing, URL Pharma will be managed by Takeda Pharmaceuticals U.S.A., Inc.

URL Pharma had revenues of nearly $600 million in 2011. Its lead product Colcrys, used to treat and prevent gout flares, had sales of more than $430 million for that year.

“This acquisition expands Takeda’s gout treatment portfolio and leverages our expertise in primary care,” said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. “Gout affects more than eight million Americans, and the prevalence of gout is rising. We are pleased to have URL Pharma’s Colcrys added to our product portfolio and look forward to further realizing our goal of helping patients by providing multiple treatment options to manage the symptoms of acute and chronic gout in the U.S.”

“URL Pharma is pleased to become a part of a leading research-based global pharmaceutical company,” said Richard H. Roberts, M.D., Ph.D., chief executive officer, and chairman of the board, URL Pharma.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters